CULLINAN THERAPEUTICS, INC. Current Assets
CULLINAN THERAPEUTICS, INC. (CGEM) had Current Assets of $341.97 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-06
- 2026-06-30: Assets, Current $341.97M.
- 2026-03-31: Assets, Current $361.41M.
- 2025-12-31: Assets, Current $386.76M.
- 2025-09-30: Assets, Current $342.24M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $341.97M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $361.41M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $386.76M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $342.24M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $275.91M 10-Q · filed 2025-08-07 |
| 2025-03-31 | $317.77M 10-Q · filed 2025-05-08 |
| 2024-12-31 | $414.67M 10-K · filed 2026-03-10 |
| 2024-09-30 | $592.04M 10-Q · filed 2024-11-07 |
| 2024-06-30 | $677.80M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $445.72M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $480.19M 10-K · filed 2025-02-27 |
| 2023-09-30 | $476.71M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $498.24M 10-Q · filed 2023-08-10 |
| 2023-03-31 | $399.03M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $474.47M 10-K · filed 2024-03-14 |
| 2022-09-30 | $582.08M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $622.84M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $322.31M 10-Q · filed 2022-05-16 |
| 2021-12-31 | $296.56M 10-K · filed 2023-03-09 |
| 2021-09-30 | $328.84M 10-Q · filed 2021-11-09 |
| 2021-06-30 | $344.47M 10-Q · filed 2021-08-10 |
| 2021-03-31 | $447.29M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $212.28M 10-K · filed 2022-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |